{"nctId":"NCT01084876","briefTitle":"Demonstrate Efficacy and Safety of Metastatic Breast Cancer","startDateStruct":{"date":"2010-06","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer"],"count":475,"armGroups":[{"label":"CT-P6 & Paclitaxel","type":"EXPERIMENTAL","interventionNames":["Drug: CT-P6","Drug: Paclitaxel"]},{"label":"Herceptin & Paclitaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Herceptin","Drug: Paclitaxel"]}],"interventions":[{"name":"CT-P6","otherNames":[]},{"name":"Herceptin","otherNames":["Trastuzumab"]},{"name":"Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are females\n* Have Her 2 over-expression\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\nExclusion Criteria:\n\n* Current clinical or radiographic evidence central nervous system (CNS) metastases\n* Current Known infection\n* Pregnant or nursing mother","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate","description":"Best Overall Response (BOR) was derived from the overall response across all time points until after Cycle 8 using Independent Tumor Review Committee (ITRC) data in the FAS. Objective Response Rate (ORR) was defined as the number of patients with a BOR of complete response (CR) or partial response (PR) divided by the number of patients in the corresponding population, as assessed by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression","description":"Time from randomization to determined progressive disease, as assessed by RECIST version 1.1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.07","spread":null},{"groupId":"OG001","value":"12.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.99","spread":null},{"groupId":"OG001","value":"11.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response","description":"Time from randomization to observed tumor response (Complete Response or Partial Response), as assessed by RECIST 1.1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":null},{"groupId":"OG001","value":"1.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"1.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"Time from randomization to radiological progression or death from any cause, as assessed by RECIST 1.1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.99","spread":null},{"groupId":"OG001","value":"11.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The number of days between the date of randomization and the date of death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.82","spread":null},{"groupId":"OG001","value":"26.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoints; Cardiotoxicity","description":"Mean change from baseline to endpoint assessment in left ventricular ejection fraction (LVEF) (%)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"6.56"},{"groupId":"OG001","value":"-4.98","spread":"6.54"}]}]}]},{"type":"SECONDARY","title":"Safety Endpoints; Immunogenicity","description":"Assessed by the proportion of patients with development of antibodies to study drug (positive anti-drug antibody \\[ADA\\] results after the first study drug infusion)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Endpoints; Ctroughss","description":"Trough concentration at steady state","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":"24.5"},{"groupId":"OG001","value":"24.2","spread":"27.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":244},"commonTop":["Alopecia","Neutropenia","Neuropathy peripheral","Peripheral sensory neuropathy","Myalgia"]}}}